DEXLEVO First in Asia to Win BEST Injectable Award at AMWC, the World's Largest Congress for Aesthetic Anti-aging
The aesthetic and medical device company DEXLEVO attended the 20th AMWC (Aesthetic & Anti-aging Medicine World Congress) held in Monaco and explained its products to the visitors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220502005974/en/
The aesthetic and medical device company DEXLEVO attended the 20th AMWC (Aesthetic & Anti-aging Medicine World Congress) held in Monaco and explained its products to the visitors. (Photo: Business Wire)
The world's first fully liquid PCL (polycaprolactone) injectable, GOURI developed by DEXLEVO, an aesthetic and medical device company, was the first in Asia to be chosen as Best Injectable in the category at the 20th AMWC (Aesthetic & Anti-aging Medicine World Congress) held in Monaco from March 31 to April 2, 2022.
AMWC is one of the world's most prestigious aesthetic and anti-aging congresses. More than 20,000 visitors from more than 200 countries worldwide, including dermatologists, attend the event every year to share the latest trends in aesthetic and anti-aging products and industry trends.
DEXLEVO launched GOURI, the world's first fully liquid PCL injectable, at the AMWC in 2021. Attending AMWC for the second year, it won the Best Injectable award for the first time as an Asian company at the AMWC Awards, having its unique technology and products recognized on the world stage. For the AMWC Awards, the AMWC Committee reviews and chooses the candidate products, judged by votes from dermatologists and industry workers around the world. At this year's review, DEXLEVO was nominated alongside prominent global beauty companies such as Allergan, Merz, Fillmed, and Aptos, proving its competence in the global market.
More than 150 doctors and companies visited DEXLEVO's booth and showed great interest in GOURI, which provides a fundamental solution to anti-aging.
Under the theme of "1st Liquid PCL-What, When, Why?", Mexican dermatologist Dr. Arturo Vela said, "The beauty market now wants naturalness. DEXLEVO's GOURI is the world's first fully liquid PCL injectable and the safest anti-aging product that meets consumer needs." Croatian dermatologist Dr. Dinko Kaliterna gave a treatment lecture at the congress under the theme "Skin Rejuvenation with Liquid PCL," saying, "GOURI is safer than competing products and its treatment is very convenient. Also, patient’s satisfaction with the procedure is high due to the natural collagen regeneration effect."
An official from DEXLEVO said, "As the trend in the beauty market changes, more companies are showing interest compared to last year's AMWC. Since the global market is showing increasing interest in GOURI, we plan to support marketing to become a leader in anti-aging products."
DEXLEVO's GOURI is the world's first fully liquid type PCL injectable of polycaprolactone (PCL), a biodegradable polymer material, that spreads naturally throughout the face and around the eyes when injected into the skin, forming a three-dimensional matrix and causing collagen production.
With the launch of AMWC in September 2021, DEXLEVO is selling and contracting GOURI in more than 40 countries and will participate as a platinum sponsor in IMCAS 2022, to be held in Paris in June this year, to accelerate marketing activities and expand the global market.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220502005974/en/
Contact information
DEXLEVO
Marketing Department
Chris Jeong
chrisjeong@dexlevo.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 09:44:00 EET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
Incyte Japan Announces Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 09:42:00 EET | Press release
Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable
GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 09:30:00 EET | Press release
Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus
Hisense Joins HEVC Advance Patent Pool22.12.2025 04:06:00 EET | Press release
Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec
Textron Aviation Defense Secures First Contract to Deliver Beechcraft T-6 Texan II Integrated Training System to Japan22.12.2025 03:00:00 EET | Press release
Textron Aviation Defense LLC, a Textron Inc. (NYSE:TXT) company, today announced that the company has finalized its first contract to deliver the Beechcraft T-6JP Texan II integrated training system to Japan’s Air Self-Defense Force (JASDF), in coordination with Kanematsu Corporation. The initial contract includes two Beechcraft T-6JP Texan II aircraft and instructor pilot and aircraft maintainer training materials. Deliveries of the first two aircraft are scheduled for 2029, with additional contracts anticipated. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251221925354/en/ The Beechcraft T-6 Texan II is designed and manufactured by Textron Aviation Defense LLC, a wholly owned subsidiary of Textron Aviation Inc. “This contract marks a pivotal step in strengthening Japan’s next-generation pilot training capabilities,” said Travis Tyler, president and CEO, Textron Aviation Defense. “We’re honored to support the Japan Air Se
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
